Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
flecainide + metoprolol
- Development stage
- Unknown
- Lead developer
- 3M
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Flecainide + metoprolol is a combination therapy used primarily for rhythm control in patients with atrial fibrillation and other supraventricular arrhythmias. Flecainide is a class 1C antiarrhythmic agent that works by blocking fast inward sodium channels during phase 0 of cardiac depolarization, prolonging the refractory period and stabilizing cardiac electrical activity. It also inhibits delayed rectifier potassium channels and ryanodine calcium channels, further affecting myocardial action potentials. Metoprolol is a beta-blocker that reduces heart rate and myocardial contractility by antagonizing beta1 adrenergic receptors in the heart. The combination improves rhythm control effectiveness in persistent symptomatic atrial fibrillation and increases tolerability compared to monotherapy[2][3][5]. This regimen requires careful monitoring due to additive effects on cardiac conduction, which can increase the risk of bradycardia or other conduction abnormalities[1][4].
- Brand names
- Metoprolol Succinate ER
- Other names
- flecainide + metoprolol
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)ADRB1 (β1)
Beyond the preview
Go deeper on flecainide + metoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on flecainide + metoprolol.